



Cannabis & the Older Adult

Special Edition

Information for Health Care Professionals: Cannabis (Marijuana, Marijuana) and the Cannabinoids

https://sagelink.ca/information_for_health_care_professionals_cannabis

This resource from the Government of Canada is a summary of peer-reviewed literature and international reviews focused on the potential therapeutic uses and harmful effects of cannabis and cannabinoids. **(OPEN ACCESS)**

Efficacy and Safety of Medical Cannabinoids in Older Subjects: A Systematic Review

<https://www.sciencedirect.com/science/article/pii/S1568163714000166?via%3Dihub>

This article describes a systematic review which aimed to integrate the evidence on indications for, efficacy, safety and pharmacokinetics of medical cannabinoids in older adults. **(PAID ACCESS)**

Medical Cannabis Use in the Elderly: Clinical Effectiveness and Guidelines

https://sagelink.ca/medical_cannabis_use_in_the_elderly

This rapid response report was intended to help Canadian health care decision-makers, health care professionals and others to make well-informed decisions to improve the quality of care. **(OPEN ACCESS)**

The Straight Dope on Cannabis and Older People

https://sagelink.ca/the_straight_dope_of_cannabis_and_older_people

This edition of in focus investigates some of the highs and lows of cannabis use among older people. **(OPEN ACCESS)**

Marijuana Use Among Adults 50 Years or Older in the 21st Century

https://sagelink.ca/marijuana_use_among_adults_50_years_or_older_in_the_21st_century

This review summarizes epidemiological literature on marijuana use among older adults. **(OPEN ACCESS)**

Illicit and Nonmedical Drug Use Among Older Adults: A Review

https://sagelink.ca/illicit_and_nonmedical_drug_use_among_older_adults_a_review

This article provides a review of epidemiological findings focusing on illicit drug use disorders and nonmedical use of prescription drugs in older adults 50 years and older. **(OPEN ACCESS)**

The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research

https://sagelink.ca/the_health_effects_of_cannabis_and_cannabinoids

This report aimed to provide comprehensive review of the then current evidence regarding the health effects of using cannabis and cannabis-derived products. **(OPEN ACCESS)**

Cannabis & the Older Adult

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis

https://sagelink.ca/cannabinoids_for_medical_use

The authors sought to review the benefits and adverse events of cannabinoids through a review of twenty-eight databases from inception to April 2015. **(OPEN ACCESS)**

Practical Considerations in Medical Cannabis Administration and Dosing

https://sagelink.ca/practical_considerations_in_medical_cannabis_administration_and_dosing

The authors attempted to present concise data on cannabis pharmacology related to THC and CBD including methods of administration and dosing recommendations. **(OPEN ACCESS)**

Dose-Related Neurocognitive Effects of Marijuana Use

<https://n.neurology.org/content/59/9/1337>

This publication describes the findings that very heavy use of marijuana is associated with persistent decrements in neurocognitive performance even after 28 days of abstinence. Further investigation was suggested to see if these decrements would resolve with continued abstinence or become progressively worse with continued heavy marijuana use. **(PAID ACCESS)**

Tetrahydrocannabinol for Neuropsychiatric Symptoms in Dementia: A Randomized Controlled Trial

https://sagelink.ca/tetrahydrocannabinol_for_neuropsychiatric_symptoms_in_dementia

This article reviews the findings of a randomized, double-blind, placebo-controlled study that sought evidence for the efficacy of low-dose THC in reducing neuropsychiatric symptoms of dementia. **(OPEN ACCESS)**

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders

https://sagelink.ca/systematic_review_efficacy_and_safety_of_medical_marijuana_in_selected_neurologic_disorders

This publication describes the findings of a review of medical marijuana (1948-2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy and movement disorders. **(OPEN ACCESS)**

Effects of Cannabis on Cognitive Function in Patients with Multiple Sclerosis

https://sagelink.ca/effects_of_cannabis_on_cognitive_function_in_patients_with_MS

The authors described the findings of a cross-sectional study which provided empirical evidence that prolonged use of inhaled or ingested street cannabis in patients with MS is associated with poorer performance on cognitive domains commonly affected in this population. **(OPEN ACCESS)**

Cannabinoids for the Treatment of Dementia

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007204.pub2/full>

This Cochrane systemic review aimed to determine from the available research whether cannabinoids are clinically effective in the treatment of dementia. **(PAID ACCESS)**

Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease

https://sagelink.ca/cannabinoids_for_the_tx_of_agitation_and_aggression_in_AD

This publication summarizes the literature on the evidence of using endocannabinoid system medications and their ability to modulate neuroinflammation and oxidative stress in Alzheimer's disease. **(OPEN ACCESS)**